This article is more than 5 years old. Information may no longer be current.
EPA with statins may reduce periprocedural MI in PCI
Click Here to Manage Email Alerts
Patients receiving eicosapentaenoic acid with statins before PCI experienced reduced type IVa MI compared with those receiving statins only, recent findings concluded.
The researchers aimed to investigate whether eicosapentaenoic acid (EPA), an omega-3 fatty acid, affects rates of periprocedural MI in an elective PCI setting. The full cohort included 165 of 178 consecutive patients with stable angina pectoris. Eligible participants underwent successful de novo stenting in the native coronary artery and were assigned to one of two treatment groups: statins with 1,800 mg per day of EPA, or statin monotherapy.
The final analysis included 30 patients in the study group and 32 controls. The researchers calculated post-procedural index of microcirculatory resistance (IMR) values for the two groups.
Multivariate analysis results indicated a significant and independent association between use of EPA and periprocedural MI. Low kidney function and slow flow/no reflow also demonstrated associations with periprocedural MI.
Post-procedural IMR values were 19.8 among patients receiving EPA plus statins compared with 27.8 among those in the statin-only group (P=.003).
“Pre-treatment with EPA in addition to statins significantly reduced the incidence of type IVa MI compared to statin therapy only, which may be attributed to the ability of EPA to reduce microvascular dysfunction induced by PCI,” the researchers concluded.
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts